Biocryst Pharmaceuticals (BCRX) Assets Average (2011 - 2026)

Biocryst Pharmaceuticals has reported Assets Average for 16 years, with the latest figure at $489.6 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 0.9% year-over-year to $489.6 million; the trailing twelve-month figure through Mar 2026 stood at $489.6 million (up 0.9% YoY), and the FY2025 full-year result was $502.3 million, changed 0.28% from the prior year.
• Assets Average for Q1 2026 stood at $489.6 million, up from $480.3 million in the prior quarter.
• The five-year high for Assets Average was $557.9 million in Q1 2022, with the low at $451.8 million in Q3 2025.
• Historically, Assets Average has averaged $504.3 million across 5 years, with a median of $492.4 million in 2024.
• Annual changes were most pronounced in 2022 — Assets Average surged 96.88% — and 2024, when it dropped 9.55%.
• Biocryst Pharmaceuticals' Assets Average stood at $554.3 million in 2022, then dropped by 6.2% to $519.9 million in 2023, then fell by 5.6% to $490.8 million in 2024, then declined by 2.15% to $480.3 million in 2025, then increased by 1.94% to $489.6 million in 2026.
• The last three Assets Average figures came in at $489.6 million (Q1 2026), $480.3 million (Q4 2025), and $451.8 million (Q3 2025), per Business Quant data.